Korean researchers patent new prostanoid EP2 and EP4 receptor dual antagonists for cancer
Sep. 19, 2023
Researchers from Kanaph Therapeutics Inc. and Korea Research Institute of Chemical Technology have disclosed prostanoid EP2 and/or EP4 receptor subtype dual antagonists reported to be useful for the treatment of cancer.